TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11168704

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control
Number of subjects: 468
Study: 11885079

Group type: EXPERIMENTAL
Intervention: 0.2% xylitol mouthrinse
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.5% xylitol mouthrinse
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 1% xylitol mouthrinse
Number of subjects: 98

Group type: COMPARATOR
Intervention: 1% sorbitol mouthrinse
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.1% NaF mouthrinse
Number of subjects: 98

Group type: COMPARATOR
Intervention: 1% xylitol mouthrinse and 0.1% NaF
Number of subjects: 98
Study: 8067145

Group type: EXPERIMENTAL
Intervention: Two tablets containing 100,000 binding units (BU) of the toxoid and 2,500 units of O-antigen for children 11-14 years
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Four tablets containing 200,000 BU of the toxoid and 5,000 units of O-antigen for adolescents aged 15-17 years
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Number of subjects: 143
Study: 2942062

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 30
Study: 31377461

Group type: EXPERIMENTAL
Intervention: Complete bed rest
Number of subjects: 32

Group type: COMPARATOR
Intervention: Activity restriction
Number of subjects: 32
Study: 28351962

Group type: EXPERIMENTAL
Intervention: Gly49 allele carriers
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: β-blocker-treated Gly49 carriers
Number of subjects: 926

Group type: COMPARATOR
Intervention: Non-carriers and non-β-blocker-treated individuals
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Gly49 allele carriers in SiGN
Number of subjects: 926
Study: 26755209

Group type: EXPERIMENTAL
Intervention: Clown therapy (interaction with clowns)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (entertained by parents and ED nurses)
Number of subjects: 40
Study: 25079090

Group type: EXPERIMENTAL
Intervention: PMTCT counselling at first visit
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Contraception counselling
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status to partners
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Testing for TB
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Single dose nevirapine during first ANC appointment
Number of subjects: 503
Study: 22296261

Group type: EXPERIMENTAL
Intervention: Full integration (FI) of HIV care into antenatal care (ANC) clinics
Number of subjects: 326

Group type: COMPARATOR
Intervention: Non-integrated (NI) model of HIV care
Number of subjects: 326
Study: 19240452

Group type: EXPERIMENTAL
Intervention: Female faculty evaluating male residents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Female faculty evaluating female residents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Male faculty evaluating male residents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Male faculty evaluating female residents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall evaluation by faculty of residents' clinical skills
Number of subjects: 40
Study: 17564955

Group type: EXPERIMENTAL
Intervention: 20 U of oxytocin in 30 mL of saline
Number of subjects: 79

Group type: COMPARATOR
Intervention: 30 mL of saline
Number of subjects: 79
Study: 15097300

Group type: EXPERIMENTAL
Intervention: ART + IL-2 (1 million IU subcutaneously once daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ART + IL-2
Number of subjects: 115
Study: 11594571

Group type: EXPERIMENTAL
Intervention: recombinant human interleukin‐12 (rhIL‐12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: biopsy of regressing lesions
Number of subjects: 32
Study: 9665682

Group type: EXPERIMENTAL
Intervention: Very low calorie diet with 3.0 g fat/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Very low calorie diet with 12.2 g fat/d
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Very low calorie diet (both groups)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher fat meals during the first three months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cholesterol saturation index
Number of subjects: 32
Study: 7989456

Group type: EXPERIMENTAL
Intervention: ISPx
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TSPx
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ns
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kx
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WPx
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All pancreas transplanted groups
Number of subjects: 30
Study: 2919093

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone 1.6 mg
Number of subjects: 0
Study: 4903691

Group type: EXPERIMENTAL
Intervention: Monophenylbutazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 0
Study: 30700344

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study: 27776372

Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 6 hours (Group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 12 hours (Group B)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Drainage tube indwelled for 18 hours (Group C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Early removal of wound drainage tube (within 6 to 12 hours)
Number of subjects: 101
Study: 26345710

Group type: EXPERIMENTAL
Intervention: lifestyle advice only
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: lifestyle advice plus information on estimated 10-year CHD risk based on phenotypic characteristics
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: lifestyle advice plus information on estimated 10-year CHD risk based on phenotypic and genetic characteristics
Number of subjects: 932

Group type: COMPARATOR
Intervention: no intervention (control group)
Number of subjects: 932
Study: 23603573

Group type: EXPERIMENTAL
Intervention: 2-hour antenatal education session and postnatal support for fathers
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Intervention group (after adjustment for age and hospital)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Intervention group (after adjustment for socioeconomic status)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Infants of older fathers
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Infants of fathers with high SES
Number of subjects: 699
Study: 21324093

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALRP)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Traditional laparoscopic radical prostatectomy (LRP)
Number of subjects: 128
Study: 19194119

Group type: EXPERIMENTAL
Intervention: Granisetron 0.5 mg per oral (days 2 and 3)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo on day 2 and granisetron 0.5 mg on days 3 and 4
Number of subjects: 73
Study: 17990468

Group type: EXPERIMENTAL
Intervention: Bannaitong Medicinal Tea (BNT) combined with Azasetron
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azasetron alone
Number of subjects: 64
Study: 15166968

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Peritoneovenous shunts
Number of subjects: 32
Study: 15509382

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 2

Group type: COMPARATOR
Intervention: Children
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 2
Study: 10509160

Group type: COMPARATOR
Intervention: VEGF levels in serum (VEGFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VEGF levels in EDTA plasma (VEGFEDTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VEGF levels in platelet poor plasma (VEGFPPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VEGF levels in platelet rich plasma (VEGFPRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VEGF levels in citrated plasma (VEGFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF4 levels in citrated plasma
Number of subjects: 0
Study: 8520744

Group type: EXPERIMENTAL
Intervention: New approach (NA) mechanical ventilation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional approach (C) mechanical ventilation
Number of subjects: 28
Study: 2030194

Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1217
Study: 7330436

Group type: EXPERIMENTAL
Intervention: Verbal encouragement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no verbal encouragement)
Number of subjects: 80
Study: 29878583

Group type: EXPERIMENTAL
Intervention: BAY 1142524 (1-200 mg single oral doses, 5-50 mg twice daily, 100 mg once daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 1142524 (5 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 1142524 (liquid service formulation or IR tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 1142524 (multiple dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 1142524
Number of subjects: 0
Study: 29162164

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Low serum 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 516
Study: 26888558

Group type: EXPERIMENTAL
Intervention: Non-apical lead position
Number of subjects: 2475
Study: 24767614

Group type: EXPERIMENTAL
Intervention: Brief mindfulness meditation training (3-day, 25-min per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cognitive training control program
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Brief mindfulness meditation training
Number of subjects: 66
Study: 22679718

Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 240
Study: 20138299

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 18052574

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Matched healthy control group
Number of subjects: 66
Study: 16124370

Group type: EXPERIMENTAL
Intervention: Fenspiride (2 ml/kg/day in three divided doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amoxicillin (80 mg/kg/day in three partite doses) + Oxymethazolin (0.05% nasal drops 3 x day)
Number of subjects: 40
Study: 12160337

Group type: EXPERIMENTAL
Intervention: Muscle Learning Therapy (MLT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10352334

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFO) 30-40 mg/kg by slow intravenous infusion
Number of subjects: 167
Study: 7588660

Group type: EXPERIMENTAL
Intervention: Orthogonal technique (n = 58)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Parallel technique (n = 40)
Number of subjects: 98
Study: 31088195

Group type: EXPERIMENTAL
Intervention: Single‐ and multiple‐dose injectable Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg once‐daily dosing of Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated once‐daily dosing of Ginkgolide B (GB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Ginkgolide B (GB)
Number of subjects: 0
Study: 31167616

Group type: EXPERIMENTAL
Intervention: Targeted Percutaneous Vertebroplasty (targeted PVP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional Percutaneous Vertebroplasty (traditional PVP)
Number of subjects: 42
Study: 27206964

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 22
Study: 25661338

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (in vitro)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Antimony treatment
Number of subjects: 29
Study: 23945574

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable penicillin‐gentamicin combination
Number of subjects: 0
Study: 21690436

Group type: EXPERIMENTAL
Intervention: Single-site robotic cholecystectomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional multiport laparoscopic cholecystectomy
Number of subjects: 10
Study: 19789647

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 16782974

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg and 6 mg (given 10 min before sedation)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (given 10 min before sedation)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 15255454

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation (36 mg vitamin E, 150 mg vitamin C, 9 mg beta-carotene) for 6 months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo capsule for 6 months
Number of subjects: 220
Study: 11296164

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Montelukast and Salmeterol (after 2 weeks of treatment)
Number of subjects: 20
Study: 9311490

Group type: EXPERIMENTAL
Intervention: Aerosolized lipid-extracted bovine surfactant (Alveofact) 120 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 8326047

Group type: EXPERIMENTAL
Intervention: Immediate checkup with directive‐confrontational counseling
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Immediate checkup with client‐centered counseling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Delayed checkup (waiting‐list control)
Number of subjects: 42
Study: 2878745

Group type: EXPERIMENTAL
Intervention: Intranasal synthetic LHRH
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31875687

Group type: EXPERIMENTAL
Intervention: Two complementary sets of rules governing rehabilitation delivery
Number of subjects: 285

Group type: COMPARATOR
Intervention: Conventional rehabilitation without any specified guidelines
Number of subjects: 285
Study: 30861532

Group type: EXPERIMENTAL
Intervention: PGA group (polyglycolic acid sheets and fibrin glue)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 137
Study: 28111428

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) plus Afatinib (40 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Afatinib (40 mg/day)
Number of subjects: 68
Study: 25781231

Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catecholamine Depletion (CD)
Number of subjects: 0
Study: 23967632

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Acupuncture + medication group
Number of subjects: 123
Study: 21524798

Group type: EXPERIMENTAL
Intervention: Continuous tactile communication group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Discontinuous non-periodic tactile communication group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Discontinuous periodic tactile communication group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Absent communication group
Number of subjects: 40
Study: 18981486

Group type: EXPERIMENTAL
Intervention: Composite primary outcome
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Composite secondary outcome
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Composite outcomes
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Death as an individual end point
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: P values for composite outcomes
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Revascularization as an individual end point
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Discrepancies in individual events
Number of subjects: 304
Study: 16935736

Group type: EXPERIMENTAL
Intervention: Bacteriostatic normal saline (BNS)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 221

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 221
Study: 12672713

Group type: EXPERIMENTAL
Intervention: Diet with plain water
Number of subjects: 27

Group type: COMPARATOR
Intervention: Diet without plain water
Number of subjects: 27
Study: 10755435

Group type: EXPERIMENTAL
Intervention: Functional brace with early movement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Below-knee cast
Number of subjects: 60
Study: 8884896

Group type: EXPERIMENTAL
Intervention: Oral vitamin C 1 g daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1414398

Group type: EXPERIMENTAL
Intervention: s-adenosyl-l-methionine (SAMe)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TSH response outside the normal range (7-25 uU/ml)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: absolute deviations from the mean TSH response (16 uU/ml)
Number of subjects: 32
Study: 2998975

Group type: EXPERIMENTAL
Intervention: Anti CMV IgG prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30045749

Group type: EXPERIMENTAL
Intervention: New participant-driven web application
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard reference website
Number of subjects: 200
Study: 28836009

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: General Anesthesia + Paravertebral Block (GA + PVB)
Number of subjects: 34
Study: 26295868

Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide (n=64)
Number of subjects: 108

Group type: COMPARATOR
Intervention: best supportive care (BSC) (n=44)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide (n=26 with previous PCI)
Number of subjects: 108

Group type: COMPARATOR
Intervention: best supportive care (BSC) (n=26 with previous PCI)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: tucotuzumab/cyclophosphamide
Number of subjects: 108

Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 108
Study: 23361950

Group type: EXPERIMENTAL
Intervention: TIMI score low-risk (0-2)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: TIMI score intermediate-risk (3-4)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: TIMI score high-risk (5-7)
Number of subjects: 587
Study: 22003170

Group type: EXPERIMENTAL
Intervention: Muscle-specific intervention (MUSSEL trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STOMPS trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STEPS trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (PEDALS trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STOMPS, STEPS, PEDALS trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activity-based intervention (STEPS, PEDALS trials)
Number of subjects: 0
Study: 19074946

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication surgery
Number of subjects: 357

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 357
Study: 16569544

Group type: EXPERIMENTAL
Intervention: TeleWatch (TW) monitoring
Number of subjects: 49

Group type: COMPARATOR
Intervention: Clinic-only (CO) carvedilol titration
Number of subjects: 49
Study: 14725520

Group type: EXPERIMENTAL
Intervention: Williams Airway Intubator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ovassapian Fibreoptic Intubating Airway
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both airways
Number of subjects: 60
Study: 11685160

Group type: EXPERIMENTAL
Intervention: Noetic therapy (stress relaxation, imagery, touch therapy, prayer)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Off-site prayer
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Noetic therapies
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 150
Study: 9450158

Group type: EXPERIMENTAL
Intervention: pivagabine (1800 mg orally for 30 days)
Number of subjects: 60
Study: 8156066

Group type: EXPERIMENTAL
Intervention: DonJoy Ankle Ligament Protector (ALP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aircast Sport-Stirrup (AS)
Number of subjects: 16
Study: 3376901

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (400 micrograms.kg‐1.d‐1 of intravenous Zn)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No zinc supplementation (control group)
Number of subjects: 24
Study: 30075481

Group type: EXPERIMENTAL
Intervention: Practical nutrition lessons
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 166